Natera | Signatera - Data & Applications | Natera

Detect residual disease before it spreads

Introducing the first ctDNA surveillance tool – the sooner you know, the sooner you can act

Detect residual disease before it spreads

Introducing the first ctDNA surveillance tool – the sooner you know, the sooner you can act

Detect residual disease before it spreads

Introducing the first ctDNA surveillance tool – the sooner you know, the sooner you can act

Detect residual disease before it spreads

Introducing the first ctDNA surveillance tool – the sooner you know, the sooner you can act

Powerfully predictive.

In clinical studies, a Signatera ctDNA-positive result was predictive of eventual clinical relapse in four tumor types.1-4

In patients with local or regionally advanced solid tumors who received definitive treatment, Signatera ctDNA status is a strong prognostic marker for whether the treatment received was adequate.

Determine response to treatment and relapse earlier than previously possible

Signatera ctDNA levels correlate to treatment response, which may help determine whether patients are benefiting from surgery or adjuvant therapy.1-4

 

Longitudinal ctDNA levels of locoregional CRC patients treated with surgery and adjuvant chemotherapy1

 
 

Determine response to treatment and relapse earlier than previously possible

Signatera ctDNA levels correlate to treatment response, which may help determine whether patients are benefiting from surgery or adjuvant therapy.1-4

 

Longitudinal ctDNA levels of locoregional CRC patients treated with surgery and adjuvant chemotherapy1

 
 

Determine response to treatment and relapse earlier than previously possible

Signatera ctDNA levels correlate to treatment response, which may help determine whether patients are benefiting from surgery or adjuvant therapy.1-4

 

Longitudinal ctDNA levels of locoregional CRC patients treated with surgery and adjuvant chemotherapy1

 
 

Determine response to treatment and relapse earlier than previously possible

Signatera ctDNA levels correlate to treatment response, which may help determine whether patients are benefiting from surgery or adjuvant therapy.1-4

 

Longitudinal ctDNA levels of locoregional CRC patients treated with surgery and adjuvant chemotherapy1

 
 

Early knowledge. More informed action.

Signatera ctDNA status informs treatment response and predicts disease relapse with clinically meaningful lead times across multiple tumor types.1-4

 

  Colorectal Breast NSCLC MIBC
Number of patients 125 49 24 (sub-group of 100 patients from the TRACERx Study) 68
Patient characteristics Stage I-III CRC patients treated with curative surgery and optional adjuvant therapy Stage I-III breast cancer patients who have completed definitive therapy in past 3 years Subcohort of Stage I-IIIA NSCLC patients from TRACERx study who received surgery and/or chemotherapy MIBC patients treated with neoadjuvant or first-line chemotherapy before radical cystectomy
Staging/Pathology Stage I: 5%
Stage II: 32%
Stage III:62%
HER2+: 16%
ER+: 69%
TN BC: 14%
Stage I: 42%
Stage II: 42%
Stage III: 17%
Stage at cystectomy TO/Cis/Ta: 65% T1/T2/T3/T4a: 32%
Number of blood time points tested 795 208 >200 656
Average lead time 8.7 months 9.5 months 4 months 2.8 months
Maximum lead time 16.5 months 2 years 11.5 months 8.2 months
Predictive of relapse with a positive Signatera result* 97% 100% 100% 96%

*Calculated based on all positive ctDNA samples after definitive treatment. Positive samples were counted if true relapse was confirmed with a radiological scan within one year after a positive ctDNA result. In bladder cancer patients where radiographical relapse has not yet occurred, only samples where 180 days or more of follow-up was available were include.

Early knowledge. More informed action.

Signatera ctDNA status informs treatment response and predicts disease relapse with clinically meaningful lead times across multiple tumor types.1-4

 

  Colorectal Breast NSCLC MIBC
Number of patients 125 49 24 (sub-group of 100 patients from the TRACERx Study) 68
Patient characteristics Stage I-III CRC patients treated with curative surgery and optional adjuvant therapy Stage I-III breast cancer patients who have completed definitive therapy in past 3 years Subcohort of Stage I-IIIA NSCLC patients from TRACERx study who received surgery and/or chemotherapy MIBC patients treated with neoadjuvant or first-line chemotherapy before radical cystectomy
Staging/Pathology Stage I: 5%
Stage II: 32%
Stage III:62%
HER2+: 16%
ER+: 69%
TN BC: 14%
Stage I: 42%
Stage II: 42%
Stage III: 17%
Stage at cystectomy TO/Cis/Ta: 65% T1/T2/T3/T4a: 32%
Number of blood time points tested 795 208 >200 656
Average lead time 8.7 months 9.5 months 4 months 2.8 months
Maximum lead time 16.5 months 2 years 11.5 months 8.2 months
Predictive of relapse with a positive Signatera result* 97% 100% 100% 96%

*Calculated based on all positive ctDNA samples after definitive treatment. Positive samples were counted if true relapse was confirmed with a radiological scan within one year after a positive ctDNA result. In bladder cancer patients where radiographical relapse has not yet occurred, only samples where 180 days or more of follow-up was available were include.

Early knowledge. More informed action.

Signatera ctDNA status informs treatment response and predicts disease relapse with clinically meaningful lead times across multiple tumor types.1-4

 

  Colorectal Breast NSCLC MIBC
Number of patients 125 49 24 (sub-group of 100 patients from the TRACERx Study) 68
Patient characteristics Stage I-III CRC patients treated with curative surgery and optional adjuvant therapy Stage I-III breast cancer patients who have completed definitive therapy in past 3 years Subcohort of Stage I-IIIA NSCLC patients from TRACERx study who received surgery and/or chemotherapy MIBC patients treated with neoadjuvant or first-line chemotherapy before radical cystectomy
Staging/Pathology Stage I: 5%
Stage II: 32%
Stage III:62%
HER2+: 16%
ER+: 69%
TN BC: 14%
Stage I: 42%
Stage II: 42%
Stage III: 17%
Stage at cystectomy TO/Cis/Ta: 65% T1/T2/T3/T4a: 32%
Number of blood time points tested 795 208 >200 656
Average lead time 8.7 months 9.5 months 4 months 2.8 months
Maximum lead time 16.5 months 2 years 11.5 months 8.2 months
Predictive of relapse with a positive Signatera result* 97% 100% 100% 96%

*Calculated based on all positive ctDNA samples after definitive treatment. Positive samples were counted if true relapse was confirmed with a radiological scan within one year after a positive ctDNA result. In bladder cancer patients where radiographical relapse has not yet occurred, only samples where 180 days or more of follow-up was available were include.

Early knowledge. More informed action.

Signatera ctDNA status informs treatment response and predicts disease relapse with clinically meaningful lead times across multiple tumor types.1-4

 

  Colorectal Breast NSCLC MIBC
Number of patients 125 49 24 (sub-group of 100 patients from the TRACERx Study) 68
Patient characteristics Stage I-III CRC patients treated with curative surgery and optional adjuvant therapy Stage I-III breast cancer patients who have completed definitive therapy in past 3 years Subcohort of Stage I-IIIA NSCLC patients from TRACERx study who received surgery and/or chemotherapy MIBC patients treated with neoadjuvant or first-line chemotherapy before radical cystectomy
Staging/Pathology Stage I: 5%
Stage II: 32%
Stage III:62%
HER2+: 16%
ER+: 69%
TN BC: 14%
Stage I: 42%
Stage II: 42%
Stage III: 17%
Stage at cystectomy TO/Cis/Ta: 65% T1/T2/T3/T4a: 32%
Number of blood time points tested 795 208 >200 656
Average lead time 8.7 months 9.5 months 4 months 2.8 months
Maximum lead time 16.5 months 2 years 11.5 months 8.2 months
Predictive of relapse with a positive Signatera result* 97% 100% 100% 96%

*Calculated based on all positive ctDNA samples after definitive treatment. Positive samples were counted if true relapse was confirmed with a radiological scan within one year after a positive ctDNA result. In bladder cancer patients where radiographical relapse has not yet occurred, only samples where 180 days or more of follow-up was available were include.

Incorporate ctDNA surveillance with Signatera into routine follow-up for earlier detection of relapse or to support consideration of an alternate therapy.

Signatera Billing and Customer Care: 650.489.9050
Hours of operation: Monday - Friday 7am-7pm CST and Saturday 8am-5pm CST
Email: signateracc@natera.com

Contact us

References

  1. Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.05282.
  2. Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma [published online ahead of print May 6, 2019]. J Clin Oncol. 2019. doi:10.1200/JCO.18.02052.
  3. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451.
  4. Coombes RC, Page K, Salari R, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence [published online ahead of print April 16, 2019]. Clin Cancer Res. 2019. doi:10.1158/1078-0432.CCR-18-3663.
Back to Top